In the context of the 7th anniversary of the opening of the Science and Technology Innovation Board, Zhang Leidi, general manager of China Life Insurance Equity Investment Co., Ltd., told reporters on August 10 that the company currently focuses on cutting-edge directions such as semiconductors, artificial intelligence, life science, and commercial aerospace. “These racetracks have sufficient market space, accelerate iterative innovation, and have the potential to enter the global market. We think these tracks have the potential to nurture world-class tech giants.” On this basis, Zhang Leidi further stated that the key now is to continue to introduce long-term patient capital and continue to support the long-term R&D investment and global strategic layout of enterprises with the long-term mechanism of the capital market. The Science and Technology Innovation Board has adopted many policies and measures to continuously optimize mechanisms such as mergers, acquisitions and restructuring, and equity incentives, providing increasingly perfect institutional guarantees for the growth of world-class enterprises. Looking forward to the future, with the continuous improvement of the patient capital system and the continuous optimization of the science and innovation ecosystem, the A-share market will surely spawn more leading technology companies based in China and leading the world.

In the context of the 7th anniversary of the opening of the Science and Technology Innovation Board, Zhang Leidi, general manager of China Life Insurance Equity Investment Co., Ltd., told reporters on August 10 that the company currently focuses on cutting-edge directions such as semiconductors, artificial intelligence, life science, and commercial aerospace. “These racetracks have sufficient market space, accelerate iterative innovation, and have the potential to enter the global market. We think these tracks have the potential to nurture world-class tech giants.” On this basis, Zhang Leidi further stated that the key now is to continue to introduce long-term patient capital and continue to support the long-term R&D investment and global strategic layout of enterprises with the long-term mechanism of the capital market. The Science and Technology Innovation Board has adopted many policies and measures to continuously optimize mechanisms such as mergers, acquisitions and restructuring, and equity incentives, providing increasingly perfect institutional guarantees for the growth of world-class enterprises. Looking forward to the future, with the continuous improvement of the patient capital system and the continuous optimization of the science and innovation ecosystem, the A-share market will surely spawn more leading technology companies based in China and leading the world.